SCHEMBL268872

SCHEMBL268872

Cc1cccc(C=NNC(=O)c2cc(Br)ccc2NC(=O)c2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
LMNA P02545 2/20 0.54
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 1/20 0.54
PLEC Q15149 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ESRRG P62508 6/20 0.49
MGAM O43451 1/20 0.47
GAA P10253 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47
NR1H4 Q96RI1 2/20 0.46
MAPT P10636 1/20 0.45
DUSP3 P51452 1/20 0.45
PTPN5 P54829 1/20 0.45
PTPN11 Q06124 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268871 1.00 RAB9A (0.65) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL267875 0.88 SMN1; SMN2 (0.64) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL267876 0.88 SMN1; SMN2 (0.64) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL266914 0.87 RAB9A (0.63) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL266915 0.87 RAB9A (0.63) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL268616 0.84 RAB9A (0.59) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL268617 0.84 RAB9A (0.59) RAB9ASMN1; SMN2LMNAKMT2ANPC1
SCHEMBL268977 0.84 RAB9A (0.58) RAB9ASMN1; SMN2KMT2ANPC1NPSR1
SCHEMBL268976 0.84 RAB9A (0.58) RAB9ASMN1; SMN2KMT2ANPC1NPSR1
SCHEMBL12868894 0.83 RAB9A (0.75) RAB9ASMN1; SMN2LMNAKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885SMN1; SMN2 3975/4885LMNA 2001/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885LMNA 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.